Genmab A/S Dkk (GNMSF) 84.4000 $GNMSF Major Sha
Post# of 273257
Posted On: 07/11/2015 6:32:46 PM
Genmab A/S Dkk (GNMSF) 84.4000 $GNMSF
Major Shareholder Announcement for Genmab A/S
GlobeNewswire - Fri Jul 10, 10:54AM CDT
Genmab A/S (OMX:GEN) announces under reference to Section 29 of the Danish Securities Trading Act that ATP has informed us that ATP and AES as of July 10, 2015 have reduced their ownership of the share capital and voting rights in Genmab A/S to below the 5% threshold.
GEN: 6.52 (+0.17)
Genmab Announces Completion of Rolling Submission of Biologics License Application for Daratumumab in Multiple Myeloma and Achievement of a USD 15 Million Milestone
GlobeNewswire - Thu Jul 09, 12:53PM CDT
-- Submission of rolling BLA to US FDA for daratumumab in multiple myeloma completed by Janssen Biotech, Inc.
GEN: 6.52 (+0.17)
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Pipeline Review, H1 2015 - 27 Companies & 33 Drug profiles
M2 - Thu Jul 09, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hdmmpc/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Antisense Therapeutics Limited - Biogen, Inc. - Cognosci, Inc. - F. Hoffmann-La Roche Ltd. - Forward Pharma A/S - Genmab A/S - GlaxoSmithKline plc - Iltoo Pharma - Mapi Pharma Ltd. - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Nuron Biotech, Inc. - Octapharma AG - Opexa Therapeutics, Inc. - RedHill Biopharma Ltd. - Sanofi - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - XenoPort, Inc. - Zydus Cadila Healthcare Limited Drug Profiles - (rifabutin clarithromycin clofazimine) - aldesleukin - ATL-1102 - ATXMS-1467 - AZ-17 - Cell Therapy for Relapsing Remitting Multiple Sclerosis - COG-133 - daclizumab - diazoxide - dimethyl fumarate - estriol - Gene Therapy for Relapsing and Remitting Multiple Sclerosis - glatiramer acetate ER - GSK-239512 - Guanabenz - HR-411 - hydralazine - imilecleucel-t - immune globulin (human) - interferon beta-1b - laquinimod sodium - MEDI-551 - MT-1303 - ofatumumab - olesoxime - opicinumab - Pegylated Interferon-Beta-1b - ponesimod - siponimod - Small Molecule to Target CTLA4 and IFNGR for RRMS - vatelizumab - VAY-736 - XP-23829 For more information visit http://www.researchandmarkets.com/research/hdmmpc/relapsing
MAPI: (), RDHL: 18.46 (+0.11), GSK: 42.45 (+0.65), XNPT: 6.79 (+0.16), SYN: 3.04 (+0.19), OPXA: 0.44 (-0.01), FWP: 39.47 (+1.55), TEVA: 61.38 (-0.75), ABBV: 69.23 (+1.26), NVS: 103.22 (+3.20)
Lung Adenocarcinoma Pipeline Review, H1 2015 - 19 Companies & 27 Drug Profiles
M2 - Thu Jul 09, 6:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3vrdth/lung) has announced the addition of the "Lung Adenocarcinoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Lung Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Adenocarcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - AVEO Pharmaceuticals, Inc. - Axelar AB - Bayer AG - BioNumerik Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - DiNonA Inc. - Eisai Co., Ltd. - Genentech, Inc. - Genmab A/S - Immunomedics, Inc. - Incyte Corporation - Medisyn Technologies, Inc. - Pfizer Inc. - Sanofi - VG Life Sciences, Inc. - Vichem Chemie Research Ltd. Drug Profiles - 4-B4 - afatinib - AV-203 - AXL-1717 - AZD-6738 - BAY-1163877 - Cell Therapy to Activate CD40L and GM-CSF for Metastatic Lung Adenocarcinoma - dacomitinib - DBPR-112 - dimesna - hydroxychloroquine sorafenib tosylate - Interferon Lambda-1 Linked Fab Dimer - lenvatinib - MAG-Tn3 - MT-477 - ruxolitinib phosphate - SAR-408701 - Small Molecule for Cancer - Small Molecule to Inhibit EGFR for Oncology - Small Molecules to Activate PKM2 for Lung Adenocarcinoma - Small Molecules to Inhibit Lactate Dehydrogenase for Lung Adenocarcinoma - SNX-5422 - solitomab - Stem Cell Therapy for Oncology - TdCyd - TF-011 Monomethyl Auristatin E - Vaccine for Lung Adenocarcinoma For more information visit http://www.researchandmarkets.com/research/3vrdth/lung
IMMU: 4.20 (+0.24), PFE: 34.36 (+0.50), INCY: 108.33 (+0.22), AZN: 66.45 (+1.90), AVEO: 1.57 (unch), AMGN: 154.10 (+2.79)
Genmab Announces European Regulatory Submission for Ofatumumab as Maintenance Therapy for Relapsed CLL
GlobeNewswire - Tue Jul 07, 6:40AM CDT
Company Announcement
GEN: 6.52 (+0.17)
B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2015 - Profiles of 90 Companies
M2 - Thu Jun 11, 6:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4w5fzl/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - B-Cell Non-Hodgkin Lymphoma Overview - Therapeutics Development - B-Cell Non-Hodgkin Lymphoma - Therapeutics under Development by Companies - B-Cell Non-Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes - B-Cell Non-Hodgkin Lymphoma - Pipeline Products Glance - B-Cell Non-Hodgkin Lymphoma - Products under Development by Companies - B-Cell Non-Hodgkin Lymphoma - Products under Investigation by Universities/Institutes - B-Cell Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development - B-Cell Non-Hodgkin Lymphoma - Therapeutics Assessment - Drug Profiles - B-Cell Non-Hodgkin Lymphoma - Recent Pipeline Updates - B-Cell Non-Hodgkin Lymphoma - Dormant Projects - B-Cell Non-Hodgkin Lymphoma - Discontinued Products - B-Cell Non-Hodgkin Lymphoma - Product Development Milestones - Appendix Companies Mentioned - Affimed Therapeutics AG - Bristol-Myers Squibb Company - Emergent BioSolutions Inc. - EpiZyme, Inc. - Erytech Pharma SA - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Genmab A/S - Gilead Sciences, Inc. - GlaxoSmithKline plc - Idera Pharmaceuticals, Inc. - Immune System Therapeutics Ltd. - ImmunoGen, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Mirati Therapeutics Inc. - Molecular Templates Inc. - MorphoSys AG - Nordic Nanovector AS - Portola Pharmaceuticals, Inc. - Priaxon AG - ProNAi Therapeutics, Inc. - Redx Pharma Ltd - Regeneron Pharmaceuticals, Inc. - Respiratorius AB - Rhizen Pharmaceuticals SA - Sandoz Inc. - Sanofi - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries Limited - TG Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/4w5fzl/bcell
PTLA: 46.44 (+1.05), EBS: 33.85 (+1.10), IMGN: 14.44 (+0.25), TGTX: 18.21 (+0.08), EPZM: 23.42 (+0.45), BMY: 69.27 (+1.38), GSK: 42.45 (+0.65), IDRA: 3.49 (+0.05), GILD: 113.74 (+0.38), MRK: 57.95 (+0.57), TEVA: 61.38 (-0.75), MRTX: 31.67 (+0.81), REGN: 526.01 (+16.98)
Waldenstrom Macroglobulinemia - Pipeline Review, H1 2015 - 18 Companies & 27 Drug Profiles
M2 - Wed Jun 10, 4:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8pl7hb/waldenstrom) has announced the addition of the "Waldenstrom Macroglobulinemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Waldenstrom Macroglobulinemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Waldenstrom Macroglobulinemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - arGEN-X BV - Bayer AG - Calithera Biosciences, Inc. - Celgene Corporation - Genmab A/S - Gilead Sciences, Inc. - Idera Pharmaceuticals, Inc. - Immune System Therapeutics Ltd. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Nimbus Therapeutics, LLC - Nordic Nanovector AS - Novartis AG - Onyx Pharmaceuticals, Inc. - Pharmacyclics, Inc. Drug Profiles - ACP-196 - ARGX-110 - Betalutin - carfilzomib - CB-839 - copanlisib - DI-B4 - everolimus - FV-162 - FV-214 - GS-9973 - ibrutinib - idelalisib - IMO-8400 - INCB-39110 - INCB-40093 - IST-1097 - ixazomib citrate - lenalidomide - ofatumumab - oprozomib - pevonedistat hydrochloride - sapanisertib - selinexor - Small Molecules to Inhibit IRAK4 for Immunology and Oncology - spebrutinib besylate - venetoclax For more information visit http://www.researchandmarkets.com/research/8p...aldenstrom
PCYC: 261.25 (+1.70), INCY: 108.33 (+0.22), IDRA: 3.49 (+0.05), GILD: 113.74 (+0.38), CALA: 6.77 (unch), ABBV: 69.23 (+1.26), NVS: 103.22 (+3.20), CELGZ: 2.15 (+0.14), KPTI: 25.57 (+0.24)
J&J Initiates Filing for Multiple Myeloma Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 08, 5:24PM CDT
Janssen Research & Development, LLC, a Johnson & Johnson (JNJ) company announced that the company has initiated the rolling submission of its BLA for pipeline candidate daratumumab to the FDA.
JNJ: 99.53 (+1.13), NVS: 103.22 (+3.20)
Genmab Announces Start of Rolling Submission of Biologics License Application for Daratumumab for Double Refractory Multiple Myeloma to the FDA
GlobeNewswire - Fri Jun 05, 10:54AM CDT
-- Janssen Biotech, Inc. initiates rolling submission of BLA to U.S. FDA for daratumumab in double refractory multiple myeloma
GEN: 6.52 (+0.17)
Halozyme-AbbVie Ink Deal for ENHANZE Platform, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 04, 8:50AM CDT
Halozyme Therapeutics, Inc. (HALO) entered into a global collaboration and license agreement with AbbVie.
HALO: 22.78 (+0.38), ABBV: 69.23 (+1.26)
Genmab Gains License to Antibody Panel Targeting CD19
GlobeNewswire - Tue Jun 02, 12:28AM CDT
Company Announcement
GEN: 6.52 (+0.17), BMY: 69.27 (+1.38)
Asco - A Sirius Lead For Daratumumab
EP Vantage - at Seeking Alpha - Mon Jun 01, 12:16PM CDT
G enmab ( OTCPK:GMXAY , OTC:GNMSF investors celebrated earlier this month when Johnson & Johnson (NYSE: JNJ ) said it would file its partnered multiple myeloma project daratumumab this year based on the phase II Sirius study. Recently...
JNJ: 99.53 (+1.13), CELG: 118.84 (+1.97)
Ofatumumab and Daratumumab Data to Be Presented at 20th Congress of EHA
GlobeNewswire - Thu May 21, 9:14AM CDT
Media Release
GEN: 6.52 (+0.17)
Global Pemphigus Pipeline Report 2015 - 7 Companies & 10 Drug Profiles
M2 - Thu May 21, 6:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l4jpj9/pemphigus) has announced the addition of the "Pemphigus - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pemphigus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pemphigus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Clinuvel Pharmaceuticals Limited - Genmab A/S - HanAll Biopharma Co., Ltd. - Immunomedics, Inc. - Momenta Pharmaceuticals, Inc. - Novartis AG - PinCell srl Drug Profiles - afamelanotide - Antibody for Autoimmune Disorders and Inflammation - DP-C006 - Drugs to Target HSP27 for Autoimmune Disorders - HL-161 - ofatumumab - PC-111 - VAY-736 - veltuzumab - Pemphigus For more information visit http://www.researchandmarkets.com/research/l4jpj9/pemphigus
IMMU: 4.20 (+0.24), MNTA: 21.76 (+0.49), NVS: 103.22 (+3.20)
BioNTech Signs Co-Development and Commercialization Agreement in Immuno-Oncology
PR Newswire - Tue May 19, 1:19AM CDT
Collaboration with Genmab will focus on novel bispecific antibody products in immuno-oncology
GEN: 6.52 (+0.17)
Genmab Enters Commercial DuoBody(r) Technology Agreement With BioNTech in Field of Immuno-oncology
GlobeNewswire - Tue May 19, 12:40AM CDT
Company Announcement
GEN: 6.52 (+0.17)
HuMax-TF-ADC and Daratumumab Data to Be Presented at 2015 ASCO Annual Meeting
GlobeNewswire - Wed May 13, 4:10PM CDT
Company Announcement
GEN: 6.52 (+0.17)
Genmab's (GNMSF) CEO Jan van de Winkel on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue May 12, 7:17PM CDT
Genmab Announces Financial Results for the First Quarter of 2015
GlobeNewswire - Tue May 12, 10:11AM CDT
Interim Report First Quarter 2015
First Quarter 2015 Net Sales Figures for Arzerra(r) (Ofatumumab)
GlobeNewswire - Wed May 06, 6:14AM CDT
-- Worldwide net sales of Arzerrain Q1 2015 totaled GBP 11.1 million
GEN: 6.52 (+0.17)
Major Shareholder Announcement for Genmab A/S
GlobeNewswire - Fri Jul 10, 10:54AM CDT
Genmab A/S (OMX:GEN) announces under reference to Section 29 of the Danish Securities Trading Act that ATP has informed us that ATP and AES as of July 10, 2015 have reduced their ownership of the share capital and voting rights in Genmab A/S to below the 5% threshold.
GEN: 6.52 (+0.17)
Genmab Announces Completion of Rolling Submission of Biologics License Application for Daratumumab in Multiple Myeloma and Achievement of a USD 15 Million Milestone
GlobeNewswire - Thu Jul 09, 12:53PM CDT
-- Submission of rolling BLA to US FDA for daratumumab in multiple myeloma completed by Janssen Biotech, Inc.
GEN: 6.52 (+0.17)
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Pipeline Review, H1 2015 - 27 Companies & 33 Drug profiles
M2 - Thu Jul 09, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hdmmpc/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Antisense Therapeutics Limited - Biogen, Inc. - Cognosci, Inc. - F. Hoffmann-La Roche Ltd. - Forward Pharma A/S - Genmab A/S - GlaxoSmithKline plc - Iltoo Pharma - Mapi Pharma Ltd. - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Nuron Biotech, Inc. - Octapharma AG - Opexa Therapeutics, Inc. - RedHill Biopharma Ltd. - Sanofi - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - XenoPort, Inc. - Zydus Cadila Healthcare Limited Drug Profiles - (rifabutin clarithromycin clofazimine) - aldesleukin - ATL-1102 - ATXMS-1467 - AZ-17 - Cell Therapy for Relapsing Remitting Multiple Sclerosis - COG-133 - daclizumab - diazoxide - dimethyl fumarate - estriol - Gene Therapy for Relapsing and Remitting Multiple Sclerosis - glatiramer acetate ER - GSK-239512 - Guanabenz - HR-411 - hydralazine - imilecleucel-t - immune globulin (human) - interferon beta-1b - laquinimod sodium - MEDI-551 - MT-1303 - ofatumumab - olesoxime - opicinumab - Pegylated Interferon-Beta-1b - ponesimod - siponimod - Small Molecule to Target CTLA4 and IFNGR for RRMS - vatelizumab - VAY-736 - XP-23829 For more information visit http://www.researchandmarkets.com/research/hdmmpc/relapsing
MAPI: (), RDHL: 18.46 (+0.11), GSK: 42.45 (+0.65), XNPT: 6.79 (+0.16), SYN: 3.04 (+0.19), OPXA: 0.44 (-0.01), FWP: 39.47 (+1.55), TEVA: 61.38 (-0.75), ABBV: 69.23 (+1.26), NVS: 103.22 (+3.20)
Lung Adenocarcinoma Pipeline Review, H1 2015 - 19 Companies & 27 Drug Profiles
M2 - Thu Jul 09, 6:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3vrdth/lung) has announced the addition of the "Lung Adenocarcinoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Lung Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Adenocarcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - AVEO Pharmaceuticals, Inc. - Axelar AB - Bayer AG - BioNumerik Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - DiNonA Inc. - Eisai Co., Ltd. - Genentech, Inc. - Genmab A/S - Immunomedics, Inc. - Incyte Corporation - Medisyn Technologies, Inc. - Pfizer Inc. - Sanofi - VG Life Sciences, Inc. - Vichem Chemie Research Ltd. Drug Profiles - 4-B4 - afatinib - AV-203 - AXL-1717 - AZD-6738 - BAY-1163877 - Cell Therapy to Activate CD40L and GM-CSF for Metastatic Lung Adenocarcinoma - dacomitinib - DBPR-112 - dimesna - hydroxychloroquine sorafenib tosylate - Interferon Lambda-1 Linked Fab Dimer - lenvatinib - MAG-Tn3 - MT-477 - ruxolitinib phosphate - SAR-408701 - Small Molecule for Cancer - Small Molecule to Inhibit EGFR for Oncology - Small Molecules to Activate PKM2 for Lung Adenocarcinoma - Small Molecules to Inhibit Lactate Dehydrogenase for Lung Adenocarcinoma - SNX-5422 - solitomab - Stem Cell Therapy for Oncology - TdCyd - TF-011 Monomethyl Auristatin E - Vaccine for Lung Adenocarcinoma For more information visit http://www.researchandmarkets.com/research/3vrdth/lung
IMMU: 4.20 (+0.24), PFE: 34.36 (+0.50), INCY: 108.33 (+0.22), AZN: 66.45 (+1.90), AVEO: 1.57 (unch), AMGN: 154.10 (+2.79)
Genmab Announces European Regulatory Submission for Ofatumumab as Maintenance Therapy for Relapsed CLL
GlobeNewswire - Tue Jul 07, 6:40AM CDT
Company Announcement
GEN: 6.52 (+0.17)
B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2015 - Profiles of 90 Companies
M2 - Thu Jun 11, 6:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4w5fzl/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - B-Cell Non-Hodgkin Lymphoma Overview - Therapeutics Development - B-Cell Non-Hodgkin Lymphoma - Therapeutics under Development by Companies - B-Cell Non-Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes - B-Cell Non-Hodgkin Lymphoma - Pipeline Products Glance - B-Cell Non-Hodgkin Lymphoma - Products under Development by Companies - B-Cell Non-Hodgkin Lymphoma - Products under Investigation by Universities/Institutes - B-Cell Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development - B-Cell Non-Hodgkin Lymphoma - Therapeutics Assessment - Drug Profiles - B-Cell Non-Hodgkin Lymphoma - Recent Pipeline Updates - B-Cell Non-Hodgkin Lymphoma - Dormant Projects - B-Cell Non-Hodgkin Lymphoma - Discontinued Products - B-Cell Non-Hodgkin Lymphoma - Product Development Milestones - Appendix Companies Mentioned - Affimed Therapeutics AG - Bristol-Myers Squibb Company - Emergent BioSolutions Inc. - EpiZyme, Inc. - Erytech Pharma SA - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Genmab A/S - Gilead Sciences, Inc. - GlaxoSmithKline plc - Idera Pharmaceuticals, Inc. - Immune System Therapeutics Ltd. - ImmunoGen, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Mirati Therapeutics Inc. - Molecular Templates Inc. - MorphoSys AG - Nordic Nanovector AS - Portola Pharmaceuticals, Inc. - Priaxon AG - ProNAi Therapeutics, Inc. - Redx Pharma Ltd - Regeneron Pharmaceuticals, Inc. - Respiratorius AB - Rhizen Pharmaceuticals SA - Sandoz Inc. - Sanofi - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries Limited - TG Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/4w5fzl/bcell
PTLA: 46.44 (+1.05), EBS: 33.85 (+1.10), IMGN: 14.44 (+0.25), TGTX: 18.21 (+0.08), EPZM: 23.42 (+0.45), BMY: 69.27 (+1.38), GSK: 42.45 (+0.65), IDRA: 3.49 (+0.05), GILD: 113.74 (+0.38), MRK: 57.95 (+0.57), TEVA: 61.38 (-0.75), MRTX: 31.67 (+0.81), REGN: 526.01 (+16.98)
Waldenstrom Macroglobulinemia - Pipeline Review, H1 2015 - 18 Companies & 27 Drug Profiles
M2 - Wed Jun 10, 4:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8pl7hb/waldenstrom) has announced the addition of the "Waldenstrom Macroglobulinemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Waldenstrom Macroglobulinemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Waldenstrom Macroglobulinemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - arGEN-X BV - Bayer AG - Calithera Biosciences, Inc. - Celgene Corporation - Genmab A/S - Gilead Sciences, Inc. - Idera Pharmaceuticals, Inc. - Immune System Therapeutics Ltd. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Nimbus Therapeutics, LLC - Nordic Nanovector AS - Novartis AG - Onyx Pharmaceuticals, Inc. - Pharmacyclics, Inc. Drug Profiles - ACP-196 - ARGX-110 - Betalutin - carfilzomib - CB-839 - copanlisib - DI-B4 - everolimus - FV-162 - FV-214 - GS-9973 - ibrutinib - idelalisib - IMO-8400 - INCB-39110 - INCB-40093 - IST-1097 - ixazomib citrate - lenalidomide - ofatumumab - oprozomib - pevonedistat hydrochloride - sapanisertib - selinexor - Small Molecules to Inhibit IRAK4 for Immunology and Oncology - spebrutinib besylate - venetoclax For more information visit http://www.researchandmarkets.com/research/8p...aldenstrom
PCYC: 261.25 (+1.70), INCY: 108.33 (+0.22), IDRA: 3.49 (+0.05), GILD: 113.74 (+0.38), CALA: 6.77 (unch), ABBV: 69.23 (+1.26), NVS: 103.22 (+3.20), CELGZ: 2.15 (+0.14), KPTI: 25.57 (+0.24)
J&J Initiates Filing for Multiple Myeloma Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 08, 5:24PM CDT
Janssen Research & Development, LLC, a Johnson & Johnson (JNJ) company announced that the company has initiated the rolling submission of its BLA for pipeline candidate daratumumab to the FDA.
JNJ: 99.53 (+1.13), NVS: 103.22 (+3.20)
Genmab Announces Start of Rolling Submission of Biologics License Application for Daratumumab for Double Refractory Multiple Myeloma to the FDA
GlobeNewswire - Fri Jun 05, 10:54AM CDT
-- Janssen Biotech, Inc. initiates rolling submission of BLA to U.S. FDA for daratumumab in double refractory multiple myeloma
GEN: 6.52 (+0.17)
Halozyme-AbbVie Ink Deal for ENHANZE Platform, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 04, 8:50AM CDT
Halozyme Therapeutics, Inc. (HALO) entered into a global collaboration and license agreement with AbbVie.
HALO: 22.78 (+0.38), ABBV: 69.23 (+1.26)
Genmab Gains License to Antibody Panel Targeting CD19
GlobeNewswire - Tue Jun 02, 12:28AM CDT
Company Announcement
GEN: 6.52 (+0.17), BMY: 69.27 (+1.38)
Asco - A Sirius Lead For Daratumumab
EP Vantage - at Seeking Alpha - Mon Jun 01, 12:16PM CDT
G enmab ( OTCPK:GMXAY , OTC:GNMSF investors celebrated earlier this month when Johnson & Johnson (NYSE: JNJ ) said it would file its partnered multiple myeloma project daratumumab this year based on the phase II Sirius study. Recently...
JNJ: 99.53 (+1.13), CELG: 118.84 (+1.97)
Ofatumumab and Daratumumab Data to Be Presented at 20th Congress of EHA
GlobeNewswire - Thu May 21, 9:14AM CDT
Media Release
GEN: 6.52 (+0.17)
Global Pemphigus Pipeline Report 2015 - 7 Companies & 10 Drug Profiles
M2 - Thu May 21, 6:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l4jpj9/pemphigus) has announced the addition of the "Pemphigus - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pemphigus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pemphigus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Clinuvel Pharmaceuticals Limited - Genmab A/S - HanAll Biopharma Co., Ltd. - Immunomedics, Inc. - Momenta Pharmaceuticals, Inc. - Novartis AG - PinCell srl Drug Profiles - afamelanotide - Antibody for Autoimmune Disorders and Inflammation - DP-C006 - Drugs to Target HSP27 for Autoimmune Disorders - HL-161 - ofatumumab - PC-111 - VAY-736 - veltuzumab - Pemphigus For more information visit http://www.researchandmarkets.com/research/l4jpj9/pemphigus
IMMU: 4.20 (+0.24), MNTA: 21.76 (+0.49), NVS: 103.22 (+3.20)
BioNTech Signs Co-Development and Commercialization Agreement in Immuno-Oncology
PR Newswire - Tue May 19, 1:19AM CDT
Collaboration with Genmab will focus on novel bispecific antibody products in immuno-oncology
GEN: 6.52 (+0.17)
Genmab Enters Commercial DuoBody(r) Technology Agreement With BioNTech in Field of Immuno-oncology
GlobeNewswire - Tue May 19, 12:40AM CDT
Company Announcement
GEN: 6.52 (+0.17)
HuMax-TF-ADC and Daratumumab Data to Be Presented at 2015 ASCO Annual Meeting
GlobeNewswire - Wed May 13, 4:10PM CDT
Company Announcement
GEN: 6.52 (+0.17)
Genmab's (GNMSF) CEO Jan van de Winkel on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue May 12, 7:17PM CDT
Genmab Announces Financial Results for the First Quarter of 2015
GlobeNewswire - Tue May 12, 10:11AM CDT
Interim Report First Quarter 2015
First Quarter 2015 Net Sales Figures for Arzerra(r) (Ofatumumab)
GlobeNewswire - Wed May 06, 6:14AM CDT
-- Worldwide net sales of Arzerrain Q1 2015 totaled GBP 11.1 million
GEN: 6.52 (+0.17)
(0)
(0)Scroll down for more posts ▼